Yas Holding Invests in Alvotech and Agrees on a Strategic Partnership for Biosimilar Candidates
Biopharmaceutical company Alvotech announced that Abu Dhabi-based investment company, Yas Holding, has acquired a 2.5% stake in their business and signed an agreement for the exclusive partnership and supply of three Alvotech biosimilar candidates, which Yas Holding will commercialize in
Chugai Renews License to EpiVax’s ISPRI In Silico Toolkit for Immunogenicity Assessment
Chugai, one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products, integrated the advanced ISPRI toolkit into their preclinical assessment pipeline after an extended head-to-head comparison with other in silico tools in September 2013. This 3-year extension will
ADC Therapeutics enters licence option deal with Avacta Group
ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates. Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind
Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain
Grünenthal, a global leader in pain management, and Mesoblast Limited, a world leader in allogeneic cellular medicines for inflammatory diseases, announced that they have entered into a strategic partnership to develop and commercialise MPC-06-ID, a Phase III allogeneic cell therapy
INTERCURE – CANNDOC signs strategic distribution agreement with S.L.E. of TEVA Pharmaceuticals
InterCure announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva Pharmaceuticals Industries. Under terms of the agreement, S.L.E. will distribute Canndoc's GMP products to pharma clients, including hospitals,
Pharming licenses orphan drug from Novartis
Novartis AG’s small molecule phosphoinositide 3-kinase delta (PI3Kẟ) blocker CDZ173, which is in a registration-enabling study, is expected to reach the market in 2022 lastest. Activated Phosphoinositide 3-kinase Delta Syndrome (APDS) is an ultra-rare, debilitating primary immune deficiency which makes